Repligen EV/EBIT RGEN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 160×
10-year median: 113×
Against its 10-year history: 78th; percentile: 0 is its lowest day, 100 its highest
10-year range: 36.6× to 480×
Peer median: 17.8×

Repligen's EV/EBIT is 160× as of Oct 23, 2026.

That is above its ten-year median of 113×, higher than on 78% of days in the last ten years.

Over that time it ranged from 36.6× in Apr 2023 to 480× in Jul 2025.

The median for 10 biotech stocks of a similar size is 17.8×.

EV/EBIT over time

median 112.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	160×	91.6×	207×
2025	206×	176×	480×
2024	325×	83.2×	349×
2023	87.2×	36.6×	88.7×
2022	43.4×	40.5×	75.6×
2021	97.4×	90.9×	199×
2020	168×	116×	198×
2019	120×	89.1×	138×
2018	101×	94.2×	191×
2017	111×	62.0×	111×
2016	66.1×	49.9×	73.2×
2015	71.3×	39.3×	144×
2014	39.6×	13.9×	45.9×
2013	14.1×	13.2×	60.8×
2012	50.7×	44.7×	105×

Against its peers

Companies in Biotechnology nearest Repligen's size, closest first, today.

Company	EV/EBIT
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
TECHBIO-TECHNE	44.9×
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
EXELExelixis	15.4×
INCYIncyte	10.1×
UTHRUnited Therapeutics	16.1×
ALNYAlnylam Pharmaceuticals	27.9×
ADMAAdma Biologics	10.9×
ONCBeOne Medicines	42.2×
Peer median	17.8×

Where Repligen ranks

#17of 17Biotech stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Repligen

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.